Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLINDAMYCIN HCL

All products: general benefit

Other products in the same Health Canada class (J01FF) — coverage varies; not interchangeable

  • Clindamycin palmitate (Dalacin C Flavoured Granules): general benefit
  • Clindamycin (Dalacin C): general benefit, Not a benefit

Clindamycin · DIN 02400529 · 150mg · capsule

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clindamycin · DIN 02400529 Manufacturer: Sanis Health Inc.; listing date 2022-04-29 Daily cost (source): $1.7736 Health Canada: Marketed since 2022-02-11 · brand CLINDAMYCIN · ATC J01FF01 CLINDAMYCIN · form Capsule · route Oral · ingredients CLINDAMYCIN (CLINDAMYCIN HYDROCHLORIDE) 150 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Clindamycin: Formulary list price $0.2217/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2217 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88532 · Verify on the e-Formulary ↗ (DIN 02400529)

Source record
DIN 02400529: Clindamycin Raw flags: sec3=Y Item: 081228006; group id 44; item number 0100; lccId None; manufacturer id SAI Source form: Cap; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.2217; ministry $0.2217 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400529 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88532
Interchangeable products
Apo-Clindamycin · DIN 02245232 · $0.2217 Auro-Clindamycin · DIN 02436906 · $0.2217 Dalacin C · DIN 00030570 · not recorded Jamp-Clindamycin · DIN 02483734 · $0.2217 M-Clindamycin · DIN 02479923 · $0.2217 Med-Clindamycin · DIN 02462656 · $0.2217 NRA-Clindamycin · DIN 02493748 · $0.2217 Riva-Clindamycin · DIN 02468476 · $0.2217 Teva-Clindamycin · DIN 02241709 · $0.2217
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free)

RIFAXIMIN

· 1 products · Limited Use, codes 475 · strengths: 550mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bacterial endocarditis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CLINDAMYCIN PALMITATE CLINDAMYCIN PALMITATE · General benefit DALACIN C FLAVOURED GRANULES is indicated for prophylaxis against alpha-hemolytic (viridans group) streptococci before dental, oral and upper respiratory tract surgery. a) The prophylaxis of bacterial endocarditis in patients allergic to penicillin with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular dysfunction, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without regurgitation but associated with thickening and/or redundancy of the valve leaflets. b) Patients taking oral penicillin for prevention or recurrence of rheumatic fever should be given another agent such as clindamycin, for prevention of bacterial endocarditis. PM: https://pdf.hres.ca/dpd_pm/00085121.PDF; date 2026-06-23; DIN 00225851; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS TEVA-CLINDAMYCIN (clindamycin hydrochloride capsules) is indicated in the treatment of serious infections due to sensitive anaerobic bacteria, such as Bacteroides species, Peptostreptococcus, anaerobic streptococci, Clostridium species and microaerophilic streptococci. TEVA-CLINDAMYCIN is also indicated in serious infections due to sensitive gram-positive aerobic organisms (staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci) when the patient is intolerant of, or the organism is resistant to other appropriate antibiotics. TEVA-CLINDAMYCIN is indicated for the treatment of the Pneumocystis jiroveci pneumonia in patients with AIDS. Clindamycin in combination with primaquine may be used in patients who are intolerant to, or fail to respond to conventional therapy. TEVA-CLINDAMYCIN is indicated for prophylaxis against alpha-hemolytic (viridans group) streptococci before dental, oral and upper respiratory tract surgery. a) The prophylaxis of bacterial endocarditis in patients allergic to penicillin with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular dysfunction… https://pdf.hres.ca/dpd_pm/00077874.PDF PM date: February 16, 2000 Source product: TEVA-CLINDAMYCIN; DIN 02241709; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.